• Clinical Evidence

Evaluation of an IV Insulin Electronic Glucose Management System Using FDA Cleared Feature of EREI (Estimated Residual Extracellular Insulin) to Prevent Severe Hypoglycemia

Setting: Cohort of 30 community hospitals.

Objective

This retrospective review examines effects of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature on glycemic control of patients receiving intravenous insulin.

Setting

Cohort of 30 community hospitals.

Results

  • With the EREI adjustment feature enabled, median time to goal was 3.3 hours for a range of 140-180 mg/dL and 135-155 mg/dL.
  • With the EREI adjustment feature enabled, incidence of severe hypoglycemia <40 mg/dL was 0.009% of blood glucose readings for a range of 140-180 mg/dL and .0007% of blood glucose readings for a range of 135-155 mg/dL.

Conclusions

Use of the specialized EndoTool EREI adjustment feature creates the potential to eliminate severe hypoglycemia while achieving target glucose levels and provides additional safety to the dosing of intravenous insulin without the human error and confusion associated with paper protocols.

Objective

This retrospective review examines effects of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature on glycemic control of patients receiving intravenous insulin.

Setting

Cohort of 30 community hospitals.

Results
  • With the EREI adjustment feature enabled, median time to goal was 3.3 hours for a range of 140-180 mg/dL and 135-155 mg/dL.
  • With the EREI adjustment feature enabled, incidence of severe hypoglycemia <40 mg/dL was 0.009% of blood glucose readings for a range of 140-180 mg/dL and .0007% of blood glucose readings for a range of 135-155 mg/dL.
Conclusions

Use of the specialized EndoTool EREI adjustment feature creates the potential to eliminate severe hypoglycemia while achieving target glucose levels and provides additional safety to the dosing of intravenous insulin without the human error and confusion associated with paper protocols.

References

Authors

W. Patrick Burgess, PhD, MD; Laurel Fuqua, RN, MSN.

Source

Presented at International Conference on Advanced Technologies & Treatments for Diabetes. Published in Diabetes Technology & Therapeutics, Volume 22, Issue S1, p584.

Year

2020

Quick navigation
Objective
Setting
Results
Conclusions
References
Objective

This retrospective review examines effects of the specialized EndoTool EREI (estimated residual extracellular insulin) adjustment feature on glycemic control of patients receiving intravenous insulin.

Setting

Cohort of 30 community hospitals.

Results
  • With the EREI adjustment feature enabled, median time to goal was 3.3 hours for a range of 140-180 mg/dL and 135-155 mg/dL.
  • With the EREI adjustment feature enabled, incidence of severe hypoglycemia <40 mg/dL was 0.009% of blood glucose readings for a range of 140-180 mg/dL and .0007% of blood glucose readings for a range of 135-155 mg/dL.
Conclusions

Use of the specialized EndoTool EREI adjustment feature creates the potential to eliminate severe hypoglycemia while achieving target glucose levels and provides additional safety to the dosing of intravenous insulin without the human error and confusion associated with paper protocols.

References

Authors

W. Patrick Burgess, PhD, MD; Laurel Fuqua, RN, MSN.

Source

Presented at International Conference on Advanced Technologies & Treatments for Diabetes. Published in Diabetes Technology & Therapeutics, Volume 22, Issue S1, p584.

Year

2020

Short and Sweet Headlines are Best!

Related posts

Image
  • Clinical Evidence

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

Using EndoTool to Optimize Insulin Management in DKA Patients with Renal Impairment

The objective of this study was to evaluate the impact of renal insufficiency on hypoglycemia rates in patients treated for Diabetic Ketoacidosis (DKA) utilizing a computerized insulin dosing algorithm.
Image
  • Clinical Evidence

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

20 minute read

Achieving Optimal Glucose Control in Critical Care Units at Atrium Health

The objective of this study was to evaluate the impact of different blood glucose (BG) target ranges for IV insulin infusions on inpatient glucose metrics, specifically focusing on hypo and hyperglycemic events, duration of IV insulin therapy, and length of stay (LOS) in the hospital.
Image
  • Clinical Evidence

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

Atrium Health Lowers Hospital Stay for DKA Patients, Yielding $12 Million in Savings

To compare the effectiveness of EndoTool IV in reducing hospital LOS and hypoglycemia rates compared to standard insulin infusion protocols.
Get in Touch

Ready to get started?

Fill in your details and one of our friendly team members will be in touch to show you how easily EndoTool can support your hospital.

"*" indicates required fields

Name*
This field is for validation purposes and should be left unchanged.